Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Risinger from Leerink Partners maintained a Buy rating on the stock and has a $780.00 price target.
David Risinger has given his Buy rating due to a combination of factors that highlight Regeneron’s potential for growth despite some near-term challenges. One of the main reasons is the expected long-term growth in earnings per share (EPS), which is projected to increase at a compound annual growth rate of 10% from 2025 to 2030. This indicates a strong potential for profitability over the next several years, which is a positive sign for investors.
Additionally, while there are some reductions in sales projections for the Eylea franchise, Risinger notes that these are primarily due to temporary factors such as inventory adjustments and funding issues with patient support foundations. He also points out that the competitive landscape for Eylea is relatively stable until 2027, which provides some security in its market position. Despite lowering the price target from $834 to $780, the overall outlook remains optimistic, with expectations of improving perceptions and sales for Eylea HD in the latter half of 2025.
In another report released on March 31, J.P. Morgan also maintained a Buy rating on the stock with a $1,000.00 price target.